Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region

The objective of this post hoc analysis of the PROSPER trial is to evaluate OS benefit and safety of enzalutamide in patients across age and regional subgroups.

Source: European Journal of Cancer - November 13, 2021 Category: Cancer & Oncology Authors: Ugo De Giorgi, Maha Hussain, Neal Shore, Karim Fizazi, Bertrand Tombal, David Penson, Fred Saad, Eleni Efstathiou, Katarzyna Madziarska, Joyce Steinberg, Jennifer Sugg, Xun Lin, Qi Shen, Cora N. Sternberg Tags: Original Research Source Type: research